Silvia Lopez‐Lastra

This paper benchmarks the Ultima UG100 and Illumina NovaSeq platforms on FFPE tissues for various sequencing modalities, finding they produce comparable results with subtle discrepancies in non-coding transcripts.

OKN4395, a triple EP2/EP4/DP1 antagonist, restores antitumor immunity by reversing prostanoid-driven immunosuppression and synergizes with anti-PD1 therapy.

The paper compares three transcriptomic methods on FFPE tumor samples to assess their ability to detect inter- and intra-patient heterogeneity.